Results 51 to 60 of about 330,598 (225)

Exploratory Analyses of Circulating Neoplastic-Immune Hybrid Cells as Prognostic Biomarkers in Advanced Intrahepatic Cholangiocarcinoma

International Journal of Molecular Sciences
Existing clinical biomarkers do not reliably predict treatment response or disease progression in patients with advanced intrahepatic cholangiocarcinoma (ICC). Circulating neoplastic-immune hybrid cells (CHCs) have great promise as a blood-based biomarker for patients with advanced ICC.
Ranish K. Patel, Michael S. Parappilly, Brett S. Walker, Robert T. Heussner, Alice Fung, Young Hwan Chang, Adel Kardosh, Charles D. Lopez, Skye C. Mayo, Melissa H. Wong   +9 more
openaire   +2 more sources

STK25 Loss Augments Anti‐PD‐1 Therapy Efficacy by Regulating PD‐L1 Stability in Colorectal Cancer

Advanced Science, EarlyView.
This study demonstrates that STK25 depletion facilitates CRC immune escape through the inhibition of PD‐L1 Ser283 phosphorylation‐mediated ubiquitination, and promotes tumor growth. Furthermore, these findings identify STK25 as a potential therapeutic target to trigger antitumor immunity and promote immunotherapy efficacy. Abstract Tumor immune evasion
Xiaowen Qiao, Pu Xing, Hao Hao, Jiangbo Chen, Lin Song, Yifan Hou, Xinying Yang, Kai Weng, Jie Chen, Pin Gao, Tongkun Song, Hong Yang, Tianqi Liu, Yumeng Ran, Bo Chen, Wei Zhao, Jiabo Di, Zaozao Wang, Jun Zhang, Xiangqian Su, Beihai Jiang   +20 more
wiley   +1 more source

eIF4E Enriched Extracellular Vesicles Induce Immunosuppressive Macrophages through HMGCR‐Mediated Metabolic Rewiring

Advanced Science, EarlyView.
Here, it is revealed that ovarian cancer cells release extracellular vesicles enriched with eIF4E, which alters protein production in macrophages. This leads to increased expression of 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase (HMGCR), boosting cholesterol synthesis and activating an immunosuppressive pathway through X‐box binding protein 1 and ...
Sonam Mittal, Minal Nenwani, Ishaque Pulikkal Kadamberi, Sudhir Kumar, Olamide Animasahun, Jasmine George, Shirng‐Wern Tsaih, Prachi Gupta, Mona Singh, Anjali Geethadevi, Chandrima Dey, Noah Meurs, Ajay Shankaran, Pradeep Chaluvally Raghavan, Deepak Nagrath, Sunila Pradeep   +15 more
wiley   +1 more source

Lenvatinib Plus Paclitaxel as Second‐Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study

Advanced Science, EarlyView.
This study determines the maximum tolerated dose of lenvatinib in combination with paclitaxel as second‐line therapy for advanced gastric cancer patients. A dynamic network biomarker panel associated with patient prognosis and response to treatment is established.
Chenfei Zhou, Jinling Jiang, Liting Guo, Wenqi Xi, Junwei Wu, Qu Cai, Jun Ji, Feng Qi, Jun Zhang   +8 more
wiley   +1 more source

Alternative Models for Anticancer Drug Discovery From Natural Products Using Binary Tumor‐Microenvironment‐on‐a‐Chip

Advanced Science, EarlyView.
This study presents a binary tumor‐microenvironment‐on‐a‐chip (T‐MOC) system incorporating multicellular tumor spheroids (MCTs) as an alternative preclinical platform to evaluate the efficacy of anticancer natural products. The T‐MOC model reproduces in vivo drug delivery barriers and physiological conditions, enabling morphological analysis to predict
Youngwon Kim, Si Hyeon Chae, Dahae Lee, Bum Soo Lee, Jiseok Lim, Hyo‐Il Jung, Ki Hyun Kim, Bongseop Kwak   +7 more
wiley   +1 more source

Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic Cancer

Cancers
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) presents significant diagnostic and prognostic challenges, as current biomarkers frequently fail to accurately stage disease, predict rapid metastatic recurrence (rPDAC), or assess response to neoadjuvant therapy (NAT).
Ranish K. Patel, Michael Parappilly, Hannah C. Farley, Emile J. Latour, Lei G. Wang, Ashvin M. Nair, Ethan S. Lu, Zachary Sims, Byung Park, Katherine Nelson, Skye C. Mayo, Gordon B. Mills, Brett C. Sheppard, Young Hwan Chang, Summer L. Gibbs, Adel Kardosh, Charles D. Lopez, Melissa H. Wong   +17 more
openaire   +2 more sources

Lutetium‐Based Nanoprobes for Radiosensitization with Immune Microenvironment Remodeling and NIR‐II Fluorescence Imaging‐Guided Surgery in Colorectal Cancer

Advanced Science, EarlyView.
Enhancing radiosensitization, modulating the tumor immune microenvironment, and ensuring complete resection are crucial for colorectal cancer (CRC) treatment. This study presents a multifunctional NIR‐II fluorescent nanoprobe, RVLu@ICG, which enhances radiosensitization, remodels the tumor immune microenvironment, and enables precise image‐guided ...
Yongying Dang, Xianzhi Liu, Zifan Zheng, Ao Wang, Ying Huang, Zhong Luo, Haina Tian, Siyaqi Li, Qiang Luo, Peiyuan Wang, Weiling He   +10 more
wiley   +1 more source

Analysis of uveal melanoma scRNA sequencing data identifies neoplastic-immune hybrid cells that exhibit metastatic potential

bioRxiv, 2023
Ashley N. Anderson, P. Conley, Christopher Klocke, Sidharth K. Sengupta, Trinity L. Robinson, Yichen Fan, Jocelyn A. Jones, Summer L. Gibbs, Alison H. Skalet, Guanming Wu, Melissa H. Wong   +10 more
semanticscholar   +1 more source

Multiple Genomic Technologies Validate Rare Novel Variant and Direct Medical Care in Vascular Anomalies

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Some vascular anomalies, such as hamartomas associated with PTEN hamartoma tumor syndrome (PHTS) and fibroadipose vascular anomaly (FAVA, often due to PI3KCA variants), share similar clinical, radiological, and histopathological presentations that challenge clinicians to provide an accurate diagnosis.
Luciana Daniela Garlisi Torales, Kristina Woodis, Allison Britt, Lea F. Surrey, Abhay Srinivasan, Arupa Ganguly, Maria Limmina, Dong Li, Suzanne P. MacFarland, Denise M. Adams, Sarah E. Sheppard   +10 more
wiley   +1 more source

Engineered Hydrogels Revolutionize Locoregional Cancer Immunotherapy

Advanced NanoBiomed Research, EarlyView.
This review systematically summarizes the latest research progress on injectable hydrogels in cancer immunotherapy, highlighting their unique advantages in precise immune activation, local drug‐controlled release, and immune microenvironment remodeling. These features provide innovative solutions to overcome the bottlenecks of systemic side effects and
Jiyong Wei, Chunliu Huang, Zenghua Zhou, Yanni Lan   +3 more
wiley   +1 more source